According to a US cross-sectional study, every fifth hospital patient with a respiratory syncytial virus (RSV) infection develops an acute cardiovascular event. For patients with a preexisting ...
"We are the first group to show an association between a quantifiable marker of inflammation—high sensitivity C-reactive protein—and disease severity and risk of AAEs, while accounting for diet and ...
This is the sixth article in a Health Affairs Forefront short series “Understanding And Addressing Pre-Hospital Diagnostic Delays.” As the introductory article, “Building The Evidence To Assure ...
Coronary artery disease (CAD) is the leading cause of death worldwide, with acute myocardial infarction (MI) representing the ...
Basel, Switzerland: In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organisation Conference (ESOC) 2024, anti-inflammatory treatment with long-term colchicine ...
Please provide your email address to receive an email when new articles are posted on . Inflammation is a major contributor to atherosclerotic heart disease. Anti-inflammatory therapy may reduce ...
Objectives Physical activity (PA) provides protective effects against cardiovascular diseases, including ischaemic heart disease. However, recommending moderate to vigorous PA (MVPA) to patients with ...
Q: You hear a lot about inflammation these days and how it's bad for your health, but isn't it also part of how your immune system protects you and keeps you healthy? At this point, I'm not sure I ...
Please provide your email address to receive an email when new articles are posted on . Patients taking colchicine had a weighted hazard ratio of 0.82 (95% CI, 0.69-0.94) for cardiovascular events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results